Cancer drug set for NHS fast-track
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.A new drug to treat advanced kidney cancer has been fast-tracked for use on the NHS, a health watchdog said yesterday.
The National Institute for Health and Clinical Excellence (Nice) is recommending Votrient (pazopanib). Pharmaceutical giant GlaxoSmithKline has agreed to a 12.5 per discount to the NHS, following the outcome of a clinical trial, comparing the drug with Sutent (sunitinib), which is already approved.
Dr Carole Longson, from Nice, said: "Pazopanib will offer patients an additional option and, for some, a more favourable side-effect profile."
Each year more than 8,000 new cases of kidney cancer are diagnosed in the UK, and almost half will lead to death.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments